Algorae Pharmaceuticals Ltd Total Liabilities
Algorae Pharmaceuticals Ltd total liabilities. Based on the latest financial reports, Algorae Pharmaceuticals Ltd (1AI) has total liabilities worth AU$111.25K AUD (≈ $78.72K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Algorae Pharmaceuticals Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Algorae Pharmaceuticals Ltd (2004–2025)
Total liabilities of Algorae Pharmaceuticals Ltd from 2004 to 2025. This chart illustrates how Algorae Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 1AI long-term investments to assets to see how much of total assets are deployed in long-term investments.
Algorae Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Algorae Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Seker Finansal Kiralama AS
IS:SEKFK
|
Turkey | TL5.11 Billion |
|
Grupo Televisa SAB DRC
BA:TV
|
Argentina | AR$124.21 Billion |
|
Tae Won Mulsan
KO:001420
|
Korea | ₩4.42 Billion |
|
Inno Holdings Inc. Common Stock
NASDAQ:INHD
|
USA | $320.05K |
|
Ralco Corporation Bhd
KLSE:7498
|
Malaysia | RM33.58 Million |
|
Emova Group SA
PA:ALEMV
|
France | €42.01 Million |
|
GreenPro Capital Corp
NASDAQ:GRNQ
|
USA | $2.58 Million |
|
Biocardia Inc
NASDAQ:BCDA
|
USA | $2.06 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Algorae Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Algorae Pharmaceuticals Ltd assets under control.
Liquidity & Leverage Metrics
Algorae Pharmaceuticals Ltd Total Liabilities Ratios Explained
Algorae Pharmaceuticals Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Algorae Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Algorae Pharmaceuticals Ltd (2004–2025)
The table below shows the annual total liabilities of Algorae Pharmaceuticals Ltd from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$169.76K ≈ $120.11K |
-4.87% |
| 2024-06-30 | AU$178.45K ≈ $126.26K |
-60.33% |
| 2023-06-30 | AU$449.86K ≈ $318.30K |
+88.02% |
| 2022-06-30 | AU$239.26K ≈ $169.29K |
-9.74% |
| 2021-06-30 | AU$265.08K ≈ $187.56K |
-48.30% |
| 2020-06-30 | AU$512.72K ≈ $362.78K |
-68.37% |
| 2019-06-30 | AU$1.62 Million ≈ $1.15 Million |
+242.39% |
| 2018-06-30 | AU$473.47K ≈ $335.01K |
-59.74% |
| 2017-06-30 | AU$1.18 Million ≈ $832.11K |
+84.97% |
| 2016-06-30 | AU$635.80K ≈ $449.87K |
+88.30% |
| 2015-06-30 | AU$337.65K ≈ $238.91K |
-72.62% |
| 2014-06-30 | AU$1.23 Million ≈ $872.45K |
+27.64% |
| 2013-06-30 | AU$966.00K ≈ $683.51K |
-17.44% |
| 2012-06-30 | AU$1.17 Million ≈ $827.85K |
+64.47% |
| 2011-06-30 | AU$711.40K ≈ $503.36K |
+1.09% |
| 2010-06-30 | AU$703.74K ≈ $497.94K |
-27.65% |
| 2009-06-30 | AU$972.64K ≈ $688.20K |
+36.19% |
| 2008-06-30 | AU$714.19K ≈ $505.34K |
-70.44% |
| 2007-06-30 | AU$2.42 Million ≈ $1.71 Million |
-1.87% |
| 2006-06-30 | AU$2.46 Million ≈ $1.74 Million |
+204.28% |
| 2005-06-30 | AU$809.16K ≈ $572.53K |
-69.29% |
| 2004-06-30 | AU$2.63 Million ≈ $1.86 Million |
-- |
About Algorae Pharmaceuticals Ltd
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more